Technology Listings


Repurposed Receptor Blocker for the Treatment of PTSD

Application

Use of neurokinin 3 receptor antagonist, osanetant, for the prevention and treatment of post-traumatic stress disorder (PTSD) and other anxiety disorders.

Key Benefits
  • Utilizes a repurposed drug that is safe for human use.
  • Potential to treat specific PTSD symptoms better than antidepressants.
Market Summary

Post-traumatic stress disorder (PTSD) occurs in some individuals after witnessing or experiencing extreme traumatic events. Currently those suffering from PTSD are prescribed antidepressants, which have limited success in clinical trials. There are no treatments for specific PTSD symptoms and no effective method for the prevention of PTSD. There are currently only a few clinical and preclinical studies for potential treatments of PTSD.

Technical Summary

The neurokinin 3 receptor (Nk3R) pathway is involved in the abnormal fear response associated with PTSD. Inhibiting this pathway may serve as a powerful treatment for PTSD and other anxiety disorders. Fear-conditioned mice treated with osanetant, an Nk3R antagonist, showed a decrease in fear expression. Osanetant may also provide a preventative treatment for PTSD wherein osanetant given shortly after a traumatic event could decrease the likelihood of developing PTSD.  This treatment has the potential to be applicable in multiple anxiety disorders such as panic disorder, phobias, and PTSD.

Developmental Stage

Mouse models of PTSD treated with osanetant show a decrease in fear response.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized PCT - United States United States 15/320,952 12/21/2016    
Nationalized PCT - Foreign EP 15811219.3   1/17/2017    
Tech ID: 14118
Published: 1/28/2015
Category
Therapeutics

Contact
Justin Burns
Licensing Associate
Emory University
justin.burns@emory.edu

Inventor(s)
Kerry Ressler
Raul Andero Gali

Keywords
Neuroscience/Pain
Repurposed Drug